(Updates with stock price movement in the headline and first paragraph)
ADC Therapeutics (ADCT) gained as much as 4.2% in intraday trading Tuesday after the company said it had completed patient enrollment in its phase 3 confirmatory trial of Zynlonta in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
"We anticipate sharing topline results of the primary endpoint analysis by the end of 2025 once the pre-specified number of events is reached and potentially submitting our supplemental BLA to the US Food and Drug Administration in the first quarter of 2026," said Chief Medical Officer Mohamed Zaki in a statement late Monday.
The stock was up 0.8% in recent trading.
Price: 1.91, Change: +0.01, Percent Change: +0.53
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.